Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-TAX: Multi-food Oral Immunotherapy with Omalizumab
NCT02626611Phase 2Completed
- Start
- Dec 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in food allergy. Started Dec 2015; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT02626611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626611.